The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, conducts and supports biomedical research to address antimicrobial resistance, a global public health threat of increasing concern. Dr. Anthony Fauci has served as director of NIAID since 1984, advising five presidents on many domestic and global health issues.
In the fight against what are commonly known as superbugs, the institute engages in basic, translational and clinical research aimed at finding innovative solutions to better diagnose, treat, and prevent antimicrobial-resistant infections. To tackle these complex issues, NIAID collaborates with other federal agencies, academic institutions, private companies, nonprofits, and health care providers through various partnerships, including the Antibacterial Resistance Leadership Group (ARLG) and the Transatlantic Task Force on Antimicrobial Resistance (TATFAR).
Fauci answered questions from Pew about the threat of antimicrobial resistance (AMR) and the work being done by the NIAID on this front.
A. We face several hurdles in developing novel antibiotics to treat resistant infections. Gram-negative bacteria, such as Escherichia coli and Pseudomonas aeruginosa, pose a significant scientific challenge because their unique cell wall features make it difficult for antibiotics to work effectively. In addition, we have virtually exhausted traditional drug discovery resources, such as chemical libraries and finding bacteria- and fungi-derived antibiotics in the environment that can be grown easily in the laboratory. However, investigators are developing tools to identify sources of naturally-occurring antibiotics. For example, a new technology called iChip can screen previously unculturable organisms in soil.
Certain characteristics of the antibiotic market, such as short treatment duration, generally low prices and restricted access to consumers, disincentivize pharmaceutical companies from making investments in creating new drugs. In this regard, a public-private collaboration called the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), and policy initiatives, such as the “Generating Antibiotic Incentives Now” law enacted in 2012, encourage development of new antibiotics. Furthermore, even when a novel antibiotic is identified, it can be difficult to enroll participants in clinical trials because of the sporadic incidence of infections and the likelihood that hospitalized patients already will have taken antibiotics.
A. In the 1980s, a person with advanced HIV/AIDS could expect to live only a few months after diagnosis, whereas today, a 20-year-old who is newly diagnosed and treated immediately with combinations of effective antiretroviral drugs can expect to live a nearly normal lifespan. The HIV/AIDS experience teaches us that an accelerated, multidisciplinary research effort can yield enormous biomedical advances. However, such achievements require sustained funding, transparency, infrastructure development, and global collaboration among researchers, industry, nonprofits, clinical trial participants, and health care professionals.
A. NIAID supports multiple approaches to antimicrobial resistance research beyond traditional drug discovery and development. For example, scientists are exploring ways to harness the immune system to prevent infections. These strategies include developing and testing vaccines for health care-associated infections that could be administered to targeted at-risk populations. Preventing bacterial infections in the first place is the best way to avoid problems of antibiotic resistance.
Monoclonal antibodies also are being evaluated as preventative therapy and for use in combination with antibiotics in severely ill patients. Other promising approaches involve manipulating microbial communities—the diverse bacteria, fungi, and viruses that inhabit the human body—to treat infection. These include using fecal microbiota transplants to treat Clostridium difficile as well as creating “live biotherapeutics” to restore normal gut function.
Viruses that infect bacteria, called bacteriophages, also are being studied because of their ability to kill drug-resistant bacteria with high specificity, thereby preserving the microbiota by avoiding the broader antibacterial effects of many antibiotics. Finally, rather than killing bacteria, some scientists are researching how to target various virulence factors, or the factors that make bacteria dangerous to us.
In addition to researching “nontraditional” products, NIAID aims to improve diagnostic testing to ensure that patients receive the correct antibiotics. Current inappropriate use of broad-spectrum antibiotics applies selective pressure to bacteria and encourages the emergence of antimicrobial resistance. NIAID and the [Department of Health and Human Services] Office of the Assistant Secretary for Preparedness and Response (ASPR) support the Antimicrobial Resistance Diagnostic Challenge to foster innovative approaches to diagnostic tests that rapidly—within hours, rather than days—identify and characterize antibiotic-resistant bacteria and/or distinguish between viral and bacterial infections.
Q. NIAID funds antibiotic-resistance research in multiple ways. First, consistent with NIH processes, NIAID funds highly meritorious basic and translational biomedical research grants, which undergo two levels of peer review. The first level of review is carried out by a scientific review group (SRG) composed primarily of non-federal scientists who have expertise in relevant scientific disciplines and current research areas. The second is performed by NIAID’s advisory council.
Councils are composed of both scientific and public representatives chosen for their expertise, interest, or activity in matters related to health and disease. Only applications that are recommended for approval by both the SRG and the advisory council may be recommended for funding. Final funding decisions are made by the relevant institute or center directors.
In addition, NIAID identifies significant research gaps and issues funding opportunity announcements to stimulate additional investigation in these areas. For example, in fiscal year 2016, NIAID awarded approximately $5 million to 24 research projects seeking to develop nontraditional therapeutics for bacterial infections. These include bacteriophage-related projects, such as engineering phages to provide broad-spectrum coverage across several different multidrug-resistant pathogens. In fiscal year 2018, NIAID funded four projects supporting the development of novel predictive assays, models, and research tools to facilitate therapeutic discovery for select gram-negative bacteria, including Carbapenem-Resistant Enterobacteriaceae (CRE), multidrug-resistant Aceinetobacter and/or multidrug-resistant Pseudomonas aeruginosa.
NIAID also provides data and materials to researchers to enable progression of candidate vaccines, diagnostics, and therapeutics through the product development pathway. For example, NIAID provided preclinical services and sponsored a Phase 1 clinical trial of intravenous fosfomycin, a broad-spectrum antibiotic effective against many multidrug-resistant isolates (e.g., MRSA, CRE, colistin-resistant bacteria). NIAID has also provided preclinical services and technical support to awardees of the CARB-X program, which supports the discovery and early development of antibacterial products.
In addition, NIAID provides support for clinical trials of new drugs, vaccines, and treatment regimens to help mitigate the effects of resistance. For example, the ARLG has initiated over 35 clinical studies and trials, including clinical testing of new drugs to treat multidrug-resistant Gram-negative bacteria, evaluating diagnostic devices in clinical settings, evaluating the effectiveness of new antibacterial stewardship programs, and optimizing treatment regimens to reduce the emergence of resistance.
A. These funding opportunities center on translational research and/or product development. Identifying milestones for such research projects maintains a focus on discovery and development of tangible candidates (e.g., drugs and vaccines) that meet necessary performance criteria and facilitate decision-making at each stage of product development. Multidisciplinary teams bring varied expertise to projects to better anticipate and address challenges inherent to product development, such as industrial and regulatory issues. This approach facilitates efficient use of time and resources to generate effective medical countermeasures suitable for further development.
A. Scientists across the globe are actively researching various approaches to tackle antimicrobial resistance. However, valuable insights and opportunities can be overlooked if the resulting data are published and dispersed across various journals and data repositories or remain unpublished, limiting access for use and re-use by the scientific community. Rather than operating in silos, specialized information-sharing platforms allow sharing and access to data in one environment so that we can see the “big picture” and consider new scientific questions. This type of data repository has been used in cancer research through the NCI Genomic Data Commons, which allows sharing and access to cancer genomic studies.
A. Antimicrobial resistance is one of the most concerning public health threats that we face. Multiple factors have combined to create a global crisis requiring a multifaceted solution that includes development of new antibiotics. Many novel approaches to combating antimicrobial resistance are in the early stages of development. However, I am encouraged by the progress made thus far, and NIAID remains committed to the comprehensive strategies and goals laid out by various national and international groups tackling antimicrobial resistance. Importantly, as we work toward developing novel biomedical countermeasures, we also must take immediate steps to mitigate the effects of resistant bacteria through effective prevention, antimicrobial stewardship programs, and surveillance.
A collection of resources to help federal, state, and local decision-makers set an achievable agenda for all Americans
Data-driven state policy innovations across America